Chengdu Easton Biopharmaceuticals Co Ltd (SHG:688513) — Market Cap & Net Worth
Market Cap & Net Worth: Chengdu Easton Biopharmaceuticals Co Ltd (688513)
Chengdu Easton Biopharmaceuticals Co Ltd (SHG:688513) has a market capitalization of $1.29 Billion (CN¥8.82 Billion) as of September 22, 2026. Listed on the SHG stock exchange, this China-based company holds position #7884 globally and #1800 in its home market, demonstrating a 11.94% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Chengdu Easton Biopharmaceuticals Co Ltd's stock price CN¥49.98 by its total outstanding shares 176532256 (176.53 Million). Also see how large is Chengdu Easton Biopharmaceuticals Co Ltd's balance sheet for a full breakdown of the balance sheet.
Chengdu Easton Biopharmaceuticals Co Ltd Market Cap History: 2020 to 2026
Chengdu Easton Biopharmaceuticals Co Ltd's market capitalization history from 2020 to 2026. Data shows growth from $794.55 Million to $1.29 Billion (0.57% CAGR). Also see Chengdu Easton Biopharmaceuticals Co Ltd cash flow conversion for how efficiently the company converts equity into cash flow.
Chengdu Easton Biopharmaceuticals Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Chengdu Easton Biopharmaceuticals Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 688513 stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.19x
Chengdu Easton Biopharmaceuticals Co Ltd's market cap is 1.19 times its annual revenue
Latest Price to Earnings (P/E) Ratio
5.61x
Chengdu Easton Biopharmaceuticals Co Ltd's market cap is 5.61 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $794.55 Million | $921.92 Million | $178.16 Million | 0.86x | 4.46x |
| 2021 | $779.94 Million | $1.02 Billion | $232.43 Million | 0.76x | 3.36x |
| 2022 | $1.04 Billion | $1.17 Billion | $246.52 Million | 0.89x | 4.22x |
| 2023 | $1.10 Billion | $1.12 Billion | $226.57 Million | 0.99x | 4.86x |
| 2024 | $778.32 Million | $1.35 Billion | $238.23 Million | 0.58x | 3.27x |
| 2025 | $1.59 Billion | $1.33 Billion | $283.25 Million | 1.19x | 5.61x |
Competitor Companies of 688513 by Market Capitalization
Companies near Chengdu Easton Biopharmaceuticals Co Ltd in the global market cap rankings as of September 22, 2026. Review 688513 goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Chengdu Easton Biopharmaceuticals Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $129.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #336 globally with a market cap of $80.46 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $61.21 Billion USD ( AU$86.50 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #508 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $129.45 Billion | $510.72 |
| #336 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.46 Billion | $798.17 |
| #455 | CSL Ltd | AU:CSL | $61.21 Billion | AU$178.30 |
| #508 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $172.94 |
Chengdu Easton Biopharmaceuticals Co Ltd Historical Marketcap From 2020 to 2026
Between 2020 and today, Chengdu Easton Biopharmaceuticals Co Ltd's market cap moved from $794.55 Million to $ 1.29 Billion, with a yearly change of 0.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.29 Billion | -18.80% |
| 2025 | CN¥1.59 Billion | +104.28% |
| 2024 | CN¥778.32 Million | -29.36% |
| 2023 | CN¥1.10 Billion | +5.91% |
| 2022 | CN¥1.04 Billion | +33.39% |
| 2021 | CN¥779.94 Million | -1.84% |
| 2020 | CN¥794.55 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 22nd, 2026 the market cap of Chengdu Easton Biopharmaceuticals Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.29 Billion USD |
| MoneyControl | $1.29 Billion USD |
| MarketWatch | $1.29 Billion USD |
| marketcap.company | $1.29 Billion USD |
| Reuters | $1.29 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Chengdu Easton Biopharmaceuticals Co Ltd
Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of pharmaceutical products in China and internationally. The company offers active pharmaceutical ingredients; finished dosage forms, including capsules, tablets, and injections; pharmaceutical intermediates; biological drugs; and generic drugs. I… Read more